Published in Gene Therapy Weekly, August 26th, 1996
Recombinant Ad vectors are capable of efficiently infecting a broad range of host cells, including both quiescent and dividing cells. Because the adenoviral DNA does not integrate into the host cell genome, this system permits transient expression of large amounts of gene products.
The hematopoietic system offers many benefits of transduction as it may be transduced ex vivo. The transient nature of Ad vectors actually could make them the vector of choice for some gene therapy protocols (e.g., induced expression of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.